Is Molina Healthcare (MOH) overvalued or fairly valued?

MarketChacha shows Molina Healthcare's valuation in context — a trailing P/E of about 28.5, a forward P/E of about 22.5, a price-to-book of about 2.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Molina Healthcare's revenue?

Molina Healthcare reported revenue of $45.4B for FY2025, with net profit of $472.0M, per official filings.

What is the share price of Molina Healthcare (MOH)?

Molina Healthcare last traded at $219.72 (+4.5% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Molina Healthcare

MOH · NYSE · Healthcare · United States

Snapshot

TickerMOH

ExchangeNYSE

SectorHealthcare

IndustryHealthcare Plans

CountryUnited States

Employees19,000

HeadquartersLong Beach, United States

Websitewww.molinahealthcare.com

Filings tracked18

About Molina Healthcare

Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces in the United States. It operates through Medicaid, Medicare, Marketplace, and Other segments. The company was founded in 1980 and is headquartered in Long Beach, California.

Who owns it

Insiders1.4%
Institutions98.6%
Public & other0.0%

792 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.59%
AQR Capital Management, LLC6.82%
Vanguard Portfolio Management LLC5.35%
Capital World Investors4.91%
Lingotto Investment Management LLP4.81%
Vanguard Capital Management LLC4.51%
Victory Capital Management Inc.3.79%
FMR, LLC3.58%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years only 0.65× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion0.65×

Net margin trend3.2% → 1.0%

Margin has compressed by about 2.2 points over the period — profitability is trending down.

Growth qualityrev 15% · PAT -34%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $11.9B · EPS 0.29

Est. earnings growth +123.3%

Next fiscal year

Rev $48.0B · EPS 8.55

Est. earnings growth +85.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$45.4B

Net margin

1.0%

ROE

11.6%

Revenue CAGR (2y)

+15.5%

Profit CAGR (2y)

-34.2%

EPS (FY2025)

8.92

Net profit (FY2025)

$472.0M

Ask MarketChacha about MOH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$45.4B	$472.0M	8.92	1.0%	11.6%
FY2024	$40.6B	$1.2B	20.42	2.9%	26.2%
FY2023	$34.1B	$1.1B	18.77	3.2%	25.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$10.9B	$60.0M	1.19	0.6%
2026Q1	$10.8B	$14.0M	0.27	0.1%
2025Q3	$11.5B	$79.0M	1.51	0.7%
2025Q2	$11.4B	$255.0M	4.75	2.2%
2025Q1	$11.1B	$298.0M	5.45	2.7%
2024Q3	$10.3B	$326.0M	5.65	3.2%
2024Q2	$9.9B	$301.0M	5.17	3.0%
2024Q1	$9.9B	$301.0M	5.17	3.0%
2023Q3	$8.5B	$245.0M	4.21	2.9%
2023Q2	$8.3B	$309.0M	5.35	3.7%
2023Q1	$8.1B	$321.0M	5.52	3.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/23/2026
8-K — Results of operations, Exhibits
SEC7/22/2026material
8-K — Reg FD disclosure, Exhibits
SEC6/10/2026material
8-K — Executive/director change, Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/11/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/8/2026material
10-Q filing
SEC4/23/2026
8-K — Results of operations, Exhibits
SEC4/22/2026material
8-K — Reg FD disclosure
SEC2/26/2026material
10-K filing
SEC2/10/2026
8-K — Material agreement, Material financial obligation, Material impairment, Exhibits
SEC2/6/2026material
8-K — Results of operations, Exhibits
SEC2/5/2026material

2025

8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC11/20/2025material
8-K — Reg FD disclosure, Exhibits
SEC11/18/2025material
8-K — Reg FD disclosure, Exhibits
SEC11/17/2025material
8-K — Reg FD disclosure, Exhibits
SEC11/14/2025material
10-Q filing
SEC10/23/2025
8-K — Results of operations, Exhibits
SEC10/22/2025material
8-K — Material agreement, Material financial obligation, Exhibits
SEC8/12/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.